Expression of Multidrug Resistance Gene of the Malignant Lymphoma at Nasalcavity or Pharynx Nasalis:A Clinical Study
- VernacularTitle:鼻腔、鼻咽部恶性淋巴瘤多药耐药基因表达的临床研究
- Author:
Shufang LIU
;
Qingshan ZHANG
- Publication Type:Journal Article
- Keywords:
P- glycoprotein;
Multidrug resistance gene-1;
Malignancy lymphoma in nasalcavity and pharynx nasalis;
S- P Immunohistochemistry;
Drug resistance
- From:
China Pharmacy
2001;0(11):-
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To discuss the clinical significance of the expression of P- glycoprotein(P-gp),the multidrug resistance gene - 1(MDR - 1) expression product in the malignant lymphoma of nasalcavity and pharynx nasalis.METHODS: The expression of P - gp in the malignancy lymphoma of nasalcavity and pharynx nasalis of 37 cases was detected by S - P Immunohistochemical staining,and its correlations with patents' first visit,return visit,original sites,pathological type, immunohistochemical typing and prognosis were analyzed.RESULTS:Positive P- gp expression appeared in 87.5%(7/8) of the patients for return visit vs.34.5%(10/29) for first visit and 70.0%(7/10) with malignant lymphoma at pharynx nasalis vs.37.0%(10/27) with malignant lymphoma at nasal cavity,all showing significant differences.There were also significant differences in drug resistance between the patients with positive P- gp expression and those with negative P- gp expression (88.2%(15/17) vs.10.0%(2/20)).CONCLUSION:Positive P-gp expression serves as scientific basis for clinicians in predicating drug resistance and selecting drugs and establishing schemes.
